Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
br Materials and methods br
2024-01-22

Materials and methods Results Discussion In this study, we observed that PACAP2 immunoreactivity is mainly distributed in the telencephalon, hippocampus, and cerebellum of the zebrafish brain. This distribution pattern is similar to that reported in a previous study in which PACAP immunorea
-
The H N mutation in
2024-01-22

The H373N mutation in exon 6 has not previously been reported [3], [4], [5], [6]; thus, this mutation appears to be a novel mutation. The functional expression study demonstrated that the H373N mutation results in almost complete loss of enzymatic activity. Thus, it is highly likely that the H373N m
-
lactacystin PF also a dual Aurora A and
2024-01-22

PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly lactacystin for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the MTD was defi
-
Zhang et al screened three
2024-01-22

Zhang et al. screened three thousand compounds library and found two active 3,5,6-substituted indolin-2-one molecules. Further, they designed various derivatives of this scaffold and among them compound 23 from the series was found active with 1.8 μM on Aurora-B kinase luminescent assay [53]. Jeffe
-
The Rv c EQ protein was
2024-01-22

The Rv2477c-EQ2 protein was purified from 600 ml induced cultures following the same protocol described above. Elution of the mutant protein from the affinity resin was done using 200 mM imidazole. After concentration and buffer-exchange of protein as described above, the purity of the protein was c
-
br Author contributions br Conflicts of interest The authors
2024-01-22

Author contributions Conflicts of interest The authors declare no competing financial interests. Acknowledgement This work was supported by grants from the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich/Transregio 166–Project C1 and grant CA 1014/1-1 to D.C.) and the IZKF Würzbur
-
The R pycnus arginase was identical to the published
2024-01-22

The R. pycnus arginase was 65% identical to the published B. caldovelox arginase sequence (AAB06939). Furthermore, the R. pycnus arginase gene was 62%, 45%, 36% and 22% identical to the published arginase sequences from Bacillus thuringiensis (AJI37018), Thermus thermophiles (WP_038039155), Human ar
-
The therapeutic potential of ML induced MET against cells of
2024-01-22

The therapeutic potential of ML327-induced MET against Allopurinol of mesenchymal origin has not been explored. In the present study, we hypothesized that induction of MET using ML327 would block the growth of ES cells and sensitize to TRAIL-mediated apoptosis. Herein, we report that ML327 induces a
-
br Material and methods br Results
2024-01-19

Material and methods Results Discussion Although we were not able to detect 12/15-LOX mRNA in the lungs of 12/15-LOX knockout mice substantial amounts of 15-HETE could be detected in BALF. In fact, significant synthesis of 15-HETE in 12/15-LOX mice have been already reported [17]. The redun
-
Imatinib was first approved for the treatment of
2024-01-19

Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h
-
br Disclosure br Acknowledgments br Introduction Deeper
2024-01-19

Disclosure Acknowledgments Introduction Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small SB 290157 trifluoroacetate salt that target genetic mutations known to play critical roles in the progression to metastatic disease. Mu
-
Aldose reductase AR is an NADPH
2024-01-19

Aldose reductase (AR), is an NADPH-dependent aldo-keto reductase very well studied as a catalyst of glucose conversion to sorbitol in the polyol pathway [11], [12]. In the diabetic lens characterized by chronically high levels of glucose, AR is responsible for production of high levels of sorbitol a
-
In conclusion we show that HBP is
2024-01-19

In conclusion, we show that HBP1 is phosphorylated on three sites, which control HBP1 transcriptional activity and glioblastoma cell proliferation. This phosphorylation largely depends on AKT, although other kinases may also be involved. In a previous study, we had shown that the PI3K-AKT pathway re
-
Some of the studies reported elevated ADA levels in schizoph
2024-01-19

Some of the studies reported elevated ADA levels in schizophrenia patients (SZ) undergoing treatment with antipsychotics (Dutra et al., 2010; Brunstein et al., 2007; Ghaleiha et al., 2011). However, it is unclear whether the increased serum ADA reported in these studies was the consequence of treatm
-
The major strength of this study is the large sample
2024-01-19

The major strength of this study is the large sample size which increases the statistical power to detect the likely subtle differences in peripheral methylation observed in psychiatric disorders (Olsson et al., 2010). Larger studies help provide more robust estimates of true associations, as small
14434 records 210/963 page Previous Next First page 上5页 206207208209210 下5页 Last page